Orozco, Jose M.
Krawczyk, Patrycja A. http://orcid.org/0000-0003-0653-1817
Scaria, Sonia M. http://orcid.org/0000-0002-6163-9479
Cangelosi, Andrew L.
Chan, Sze Ham http://orcid.org/0000-0002-3235-0852
Kunchok, Tenzin
Lewis, Caroline A. http://orcid.org/0000-0003-1787-5084
Sabatini, David M. http://orcid.org/0000-0002-1446-7256
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (F30CA210373, R01 CA129105, F30CA210373)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (T32GM007753, T32GM007753)
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (F31DK113665)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Howard Hughes Medical Institute
American Cancer Society
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences
Article History
Received: 17 February 2020
Accepted: 24 June 2020
First Online: 27 July 2020
Competing interests
: D.M.S. is a founder, shareholder and member of the scientific advisory board for Navitor Pharmaceuticals, which is targeting the mTORC1 pathway for therapeutic benefit. J.M.O. is a shareholder of Navitor Pharmaceuticals. The other authors declare no competing interests.